Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Open access

Abstract

The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the antimyeloma activity of IMiDs. CRBN depletion is initially cytotoxic to human myeloma cells, but surviving cells with stable CRBN depletion become highly resistant to both lenalidomide and pomalidomide, but not to the unrelated drugs bortezomib, dexamethasone, and melphalan. Acquired deletion of CRBN was found to be the primary genetic event differentiating isogenic MM1.S cell lines cultured to be sensitive or resistant to lenalidomide and pomalidomide. Gene expression changes induced by lenalidomide were dramatically suppressed in the presence of CRBN depletion, further demonstrating that CRBN is required for lenalidomide activity. Downstream targets of CRBN include interferon regulatory factor 4 (IRF4) previously reported to also be a target of lenalidomide. Patients exposed to, and putatively resistant to, lenalidomide had lower CRBN levels in paired samples before and after therapy. In summary, CRBN is an essential requirement for IMiD activity and a possible biomarker for the clinical assessment of antimyeloma efficacy.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2011-05-356063

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 19 references

Cited by

See all 607

Metadata

Authors
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., Orlowski, R. Z., & Stewart, A. K.
Affiliations
  • Mayo Clinic (US)
  • Divisions of Hematology-Oncology and
  • The University of Texas MD Anderson Cancer Center (US)
Venue
Blood
Published
2011-11-03
Volume
118
Issue
18
Pages
4771-4779
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2025656486
Cited by
607
References
19
Citations by year
2026: 11 · 2025: 27 · 2024: 24 · 2023: 30 · 2022: 35 · 2021: 56 · 2020: 37 · 2019: 36 · 2018: 40 · 2017: 41 · 2016: 36 · 2015: 53 · 2014: 62 · 2013: 78 · 2012: 37
FWCI
39.38
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (R01AG020686)
  • National Cancer Institute (R01CA133966, R01CA136671)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Keywords
cereblon, lenalidomide, pomalidomide, immunomodulators, multiple myeloma, drug resistance, IRF4, thalidomide, MM.1S cells, biomarkers, gene expression changes
MeSH terms
Bortezomib, Lenalidomide, Antineoplastic Agents, Boronic Acids, Chromosome Aberrations, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Female, Humans, Immunologic Factors, Models, Biological, Multiple Myeloma, Peptide Hydrolases, Pyrazines, Thalidomide, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, RNA, Small Interfering, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Biomarkers, Pharmacological, Comparative Genomic Hybridization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. https://app.cochat.ai/papers/10.1182/blood-2011-05-356063
The paper
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., Orlowski, R. Z., & Stewart, A. K. (2011). Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. https://doi.org/10.1182/blood-2011-05-356063

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.